Genmab AS (STU:GE9) Cyclically Adjusted PS Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:GE9 Genmab AS STU:GE9
100 GF Score
Price €257.00
GF Value €314.25
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Genmab AS  (STU:GE9) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Genmab AS Cyclically Adjusted PS Ratio Related Terms


Genmab AS Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Genmab AS's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Cyclically Adjusted PS Ratio Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47.06 35.47 20.08 10.58 11.25

Genmab AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.21 11.26 11.25 9.03 0.00

STU:GE9 vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted PS Ratio falls into.


STU:GE9
100GF Score
Genmab AS STU:GE9
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Genmab AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Genmab AS's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=16.246/122.9700*122.9700
=16.246

Current CPI (Jun. 2026) = 122.9700.

Genmab AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.792 100.200 0.972
201612 1.888 100.300 2.315
201703 0.544 101.200 0.661
201706 1.706 101.200 2.073
201709 0.680 101.800 0.821
201712 2.279 101.300 2.767
201803 1.471 101.700 1.779
201806 1.094 102.300 1.315
201809 1.287 102.400 1.546
201812 2.619 102.100 3.154
201903 1.277 102.900 1.526
201906 1.657 102.900 1.980
201909 2.134 102.900 2.550
201912 6.184 102.900 7.390
202003 1.813 103.300 2.158
202006 11.100 103.200 13.226
202009 3.501 103.500 4.160
202012 4.966 103.400 5.906
202103 3.172 104.300 3.740
202106 3.972 105.000 4.652
202109 4.636 105.800 5.388
202112 4.906 106.600 5.659
202203 4.378 109.900 4.899
202206 6.365 113.600 6.890
202209 8.277 116.400 8.744
202212 12.137 115.900 12.877
202303 5.886 117.300 6.171
202306 8.530 116.400 9.011
202309 9.493 117.400 9.943
202312 10.155 116.700 10.701
202403 8.495 118.400 8.823
202406 11.158 118.500 11.579
202409 11.542 118.900 11.937
202412 13.615 118.900 14.081
202503 10.345 120.200 10.583
202506 12.937 120.700 13.180
202509 14.028 121.600 14.186
202512 14.315 121.200 14.524
202603 12.137 121.680 12.266
202606 16.246 122.970 16.246

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Genmab AS (STU:GE9) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of €257.00 is trading 18.2% below its estimated GF Value™ of €314.25. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for STU:GE9:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €314.25 vs. price of €257.00 (18.2% below fair value)
  • GF Score™: 100/100 with 5 warning signs

No single metric tells the full story. See the STU:GE9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
100GF Score

Get the complete analysis for STU:GE9

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€257.00
Price
€314.25
GF Value